A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer

Clinical Cancer Research

Volumn 17, Issue 18, 2011, Pages 5991-5999

  Sung, Wen Wei ^a   Wang, Yao Chen ^a,b   Cheng, Ya Wen ^a   Lee, Ming Ching ^c   Yeh, Kun Tu ^a,d   Wang, Lee ^a   Wang, John ^c   Chen, Chih Yi ^e   Lee, Huei ^a,b  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND; MESSENGER RNA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; EARLY CANCER; FASL GENE; FEMALE; GENE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENOTYPE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; RECURRENCE RISK; RELAPSE FREE SURVIVAL; SURVIVAL;

AGED; AGED, 80 AND OVER; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; FAS LIGAND PROTEIN; FEMALE; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; T-LYMPHOCYTES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80052825094     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0227     Document Type: Article

References (46)

1. Ju ST, Panka DJ, Cui H, Ettinger R, el-Khatib M, Sherr DH, et al. Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995;373:444-8.
2. Bennett MW, O'Connell J, O'Sullivan GC, Roche D, Brady C, Kelly J, et al. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer. Gut 1999;44:156-62. (Pubitemid 29119356)
3. Huber V, Fais S, Iero M, Lugini L, Canese P, Squarcina P, et al. Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology 2005;128:1796-804. (Pubitemid 40824690)
4. Minas V, Rolaki A, Kalantaridou SN, Sidiropoulos J, Mitrou S, Petsas G, et al. Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation. Br J Cancer 2007;97: 637-45. (Pubitemid 47339889)
5. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996;184:1075-82.
6. Rasper DM, Vaillancourt JP, Hadano S, Houtzager VM, Seiden I, Keen SL, et al. Cell death attenuation by 'Usurpin', a mammalian DEDcaspase homologue that precludes caspase-8 recruitment and activation by the CD-95 (Fas, APO-1) receptor complex. Cell Death Differ 1998;5:271-88.
7. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997;388:190-5. (Pubitemid 27297457)
8. Green DR. Cancer: a wolf in wolf's clothing. Nature 2010;465:433.
9. Chen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C, et al. CD95 promotes tumour growth. Nature 2010;465:492-6.
10. Peter ME, Budd RC, Desbarats J, Hedrick SM, Hueber AO, Newell MK, et al. The CD95 receptor: apoptosis revisited. Cell 2007;129: 447-50. (Pubitemid 46660984)
11. Park SM, Schickel R, Peter ME. Nonapoptotic functions of FADDbinding death receptors and their signaling molecules. Curr Opin Cell Biol 2005;17:610-6. (Pubitemid 41540410)
12. Alappat EC, Feig C, Boyerinas B, Volkland J, Samuels M, Murmann AE, et al. Phosphorylation of FADD at serine 194 by CKIalpha regulates its nonapoptotic activities. Mol Cell 2005;19:321-32. (Pubitemid 41074888)
13. Gilot D, Serandour AL, Ilyin GP, Lagadic-Gossmann D, Loyer P, Corlu A, et al. A role for caspase-8 and c-FLIPL in proliferation and cellcycle progression of primary hepatocytes. Carcinogenesis 2005;26: 2086-94. (Pubitemid 41672196)
14. Legembre P, Schickel R, Barnhart BC, Peter ME. Identification of SNF1/AMP kinase-related kinase as an NF-kappaB-regulated antiapoptotic kinase involved in CD95-induced motility and invasiveness. J Biol Chem 2004;279:46742-7. (Pubitemid 39518322)
15. Barnhart BC, Legembre P, Pietras E, Bubici C, Franzoso G, Peter ME. CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J 2004;23:3175-85. (Pubitemid 39093611)
16. Mitsiades CS, Poulaki V, Fanourakis G, Sozopoulos E, McMillin D, Wen Z, et al. Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation. Clin Cancer Res 2006;12:3705-12. (Pubitemid 44000250)
17. Wu J, Metz C, Xu X, Abe R, Gibson AW, Edberg JC, et al. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients.J Immunol 2003;170:132-8.
18. Zhang X, Miao X, Sun T, Tan W, Qu S, Xiong P, et al. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet 2005;42:479-84. (Pubitemid 40847235)
19. Zhang B, Sun T, Xue L, Han X, Zhang B, Lu N, et al. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 2007;28:1067-73. (Pubitemid 47072192)
20. Sun T, Miao X, Zhang X, Tan W, Xiong P, Lin D. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 2004;96:1030-6. (Pubitemid 39162646)
21. Sun T, Zhou Y, Li H, Han X, Shi Y, Wang L, et al. FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med 2005;202:967-74. (Pubitemid 41396896)
22. Yang M, Sun T, Wang L, Yu D, Zhang X, Miao X, et al. Functional variants in cell death pathway genes and risk of pancreatic cancer. Clin Cancer Res 2008;14:3230-6.
23. Korkolopoulou P, Saetta AA, Levidou G, Gigelou F, Lazaris A, Thymara I, et al. c-FLIP expression in colorectal carcinomas: association with Fas/FasL expression and prognostic implications. Histopathology 2007;51:150-6. (Pubitemid 47083980)
24. Bebenek M, Dus D, Kozlak J. Fas and Fas ligand as prognostic factors in human breast carcinoma. Med Sci Monit 2006;12:CR457-61.
25. Lee WC, Yu MC, Chen MF. Prognostic impact of Fas ligand on hepatocellular carcinoma after hepatectomy. World J Surg 2004; 28:792-6.
26. Viard-Leveugle I, Veyrenc S, French LE, Brambilla C, Brambilla E. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma. J Pathol 2003;201:268-77. (Pubitemid 37258938)
27. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, et al. Human lung carcinomas express Fas ligand. Cancer Res 1997; 57:1007-12. (Pubitemid 27138590)
28. O'Connell J, Bennett MW, O'Sullivan GC, Roche D, Kelly J, Collins JK, et al. Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. J Pathol 1998;186:240-6. (Pubitemid 28494350)
29. Nagashima H, Mori M, Sadanaga N, Mashino K, Yoshikawa Y, Sugimachi K. Expression of Fas ligand in gastric carcinoma relates to lymph node metastasis. Int J Oncol 2001;18:1157-62.
30. Lerma E, Romero M, Gallardo A, Pons C, Muñoz J, Fuentes J, et al. Prognostic significance of the Fas-receptor/Fas-ligand system in cervical squamous cell carcinoma. Virchows Arc 2008;452:65-74.
31. Mezzanzanica D, Balladore E, Turatti F, Luison E, Alberti P, Bagnoli M, et al. CD95-mediated apoptosis is impaired at receptor level by cellular FLICE-inhibitory protein (long form) in wild-type p53 human ovarian carcinoma. Clin Cancer Res 2004;10:5202-14. (Pubitemid 39099795)
32. Cheng YW, Wu MF, Wang J, Yeh KT, Goan YG, Chiou HL, et al. Human papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53 inactivation. Cancer Res 2007;67: 10686-93. (Pubitemid 350145894)
33. Park JY, Lee WK, Jung DK, Choi JE, Park TI, Lee EB, et al. Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer. Clin Cancer Res 2009;15:1794-800.
34. Park SH, Choi JE, Kim EJ, Jang JS, Lee WK, Cha SI, et al. Polymorphisms in the FAS and FASL genes and risk of lung cancer in a Korean population. Lung Cancer 2006;54:303-8. (Pubitemid 44634149)
35. Brunner T, Mogil RJ, LaFace D, Yoo NJ, Mahboubi A, Echeverri F, et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 1995; 373:441-4.
36. Green DR, Droin N, Pinkoski M. Activation-induced cell death in T cells. Immunol Rev 2003;193:70-81. (Pubitemid 36688041)
37. Ju ST, Panka DJ, Cui H, Ettinger R, el-Khatib M, Sherr DH, et al. Fas (CD95)/FasL interactions required for programmed cell death after Tcell activation. Nature 1995;373:444-8.
38. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F. Fas counter-attack-the best form of tumor defense? Nat Med 1999; 5:267-8.
39. Okada K, Komuta K, Hashimoto S, Matsuzaki S, Kanematsu T, Koji T. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by Fas counterattack in human colorectal carcinoma and its correlation with prognosis. Clin Cancer Res 2000;6:3560-4.
40. Kase H, Aoki Y, Tanaka K. Fas ligand expression in cervical adenocarcinoma: relevance to lymph node metastasis and tumor progression. Gynecol Oncol 2003;90:70-4. (Pubitemid 37338078)
41. Mottolese M, Buglioni S, Bracalenti C, Cardarelli MA, Ciabocco L, Giannarelli D, et al. Prognostic relevance of altered Fas (CD95)-system in human breast cancer. Int J Cancer 2000;89:127-32. (Pubitemid 30185920)
42. Ekert PG, Silke J, Vaux DL. Caspase inhibitors. Cell Death Differ 1999;6:1081-6.
43. Korkolopoulou P, Goudopoulou A, Voutsinas G, Thomas-Tsagli E, Kapralos P, Patsouris E, et al. c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations. Urology 2004;63:1198-204. (Pubitemid 38746841)
44. Wilson TR, Redmond KM, McLaughlin KM, Crawford N, Gately K, O'Byrne K, et al. Procaspase 8 overexpression in non-small-cell lung cancer promotes apoptosis induced by FLIP silencing. Cell Death Differ 2009;16:1352-61.
45. McLornan DP, Barrett HL, Cummins R, McDermott U, McDowell C, Conlon SJ, et al. Prognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer. Clin Cancer Res 2010; 16:3442-51.
46. Liu X, Yue P, Schonthal AH, Khuri FR, Sun SY. Cellular FLICE inhibitory protein down-regulation contributes to celecoxib-induced apoptosis in human lung cancer cells. Cancer Res 2006;66: 11115-9. (Pubitemid 46009936)